Michigan's hepatitis C (HCV) cases have been on the decline since 2022, due to several coordinated efforts including, eliminating Medicaid restrictions, partnering with a pharmaceutical company to offer low-cost direct acting-antivirals (DAA), to hiring an academic detailer to educate medical students and providers, to creating a hepatitis C disease intervention specialist (DIS) program to link individuals to care.
This conference is supported, in part, by independent educational grants from ineligible companies. A full list of supporters is available here. All accredited content has been developed and delivered in accordance with the ACCME Standards for Integrity and Independence and the criteria of Joint Accreditation for Interprofessional Continuing Education™, and is free of commercial bias.
